Improving the tumor specificity and retention of antibody-based molecules

In Vivo

Volumn 12, Issue 1, 1998, Pages 11-21

  Adams, Gregory P ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Affinity; Monoclonal antibodies; Radiolabeling; Single chain Fv; Tumor targeting

Indexed keywords

CANCER ANTIBODY; MONOCLONAL ANTIBODY; RADIOISOTOPE; TUMOR ANTIGEN;

ANTIBODY SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; DRUG TARGETING; HUMAN; ISOTOPE LABELING; NONHUMAN;

EID: 0031979136     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Kohler GAMC: Continuous clusters of fused cells secreting antibody of predefined specificity. Nature 256: 495-497, 1975.
2. Kaminski MS, Zasady KR, Francis IR, Milik AW, Ross, GW, Moon SD, Crawford SM, Burgess JM, Petrys NA, Butchko GM et al: Radioimmunotherapy of B-cell lymphoma with 131I-anti-Bl (anti-CD20) antibody. New England J Med 329: 459-465, 1993.
3. Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB, Glenn S, Butchko G, Fisher D, Porter B, Matthews DC, Fischer LD and Bernstein D: Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. New England J Med 329: 1219-1224, 1993.
4. Jain RK: Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res (Suppl.) 50: 814s-819s, 1990.
5. Berkower I: The promise and pitfalls of monoclonal antibodies. Curr Opin Biotech 7: 622-628, 1996.
6. Huston J S, Levinson D, Mudgett-Hunter M, Tai M-S and Novotny J: Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in E coli. Proc Natl Acad Sci USA 85: 5879-5883, 1988.
7. Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, Lee S-M, Lee T, Pope SH, Riordan GS and Whitlow M: Single-chain antigen-binding proteins. Science 242: 423-426, 1988.
8. Winter G, Griffiths AD, Hawkins RE and Hoogenboom HR: Making antibodies by phage display. Annu Rev Immunol 12: 433-455, 1994.
9. Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD and Winter G: By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Biol 222: 581-597, 1991.
10. Sivolapenko GB, Douli V, Pectasides D, Skarlos D, Sirmalis G, Hussain R, Cook J, Courtenay-Luck NS, Merkouri E, Konstantinides K and Epenetos AA: Breast cancer imaging with radiolabelled peptide from complementarity-determining region of antitumor antibody. Lancet 346: 1662-1666, 1995.
11. Ward E S, Gussow D, Griffiths AD, Jones PT and Winter G: Binding activities of a repertoire of single immunoglobulin variable domains secreted from Eschenchia coli. Nature 341: 544-546, 1989.
12. Adams GP, McCartney JE, Tai M-S, Oppermann H, Huston JS, Stafford WF, Bookman MA, Fand I, Houston LL and Weiner LM: Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv, Cancer Res 53: 4026-4034, 1993.
13. Holliger P, Prospero T and Winter G 'Diabodies': small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA 90: 6444-6448, 1993.
14. Hu Shi-zhen S L, Raubitschek Andrew, Sherman Mark, Williams Lawrence E, Wong Jeffrey YC, Shively John E and Wu Anna M Minibody: a novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res 56: 3055-3061, 1996.
15. Schiffer M, Chang C-H, Naik VM and Stevens FJ: Analysis of immunoglobulin domain interactions Evidence for a dominant role of salt bridges. J Mol Biol 203: 799-802, 1988.
16. Rennke HG, Olson JL and Venkatachalam Glomerular filtration of macromolecules: Normal mechanisms and the pathogenesis of proteinuria. Contr Nephrol 24: 30-41, 1981.
17. Milenic DE, Yokota T, Filpula DR, Finkelman MAJ, Dodd SW, Wood JF, Whitlow M, Snoy P and Schlom J: Construction, binding properties, metabolism, and targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res 51: 6363-6371, 1991.
18. Wu AM, Chen W, Raubitschek AA, Willams LE, Fischer R, Hu S-z, Odom-Maryon T, Wong JYC and Shively JE: Tumor localization of anti-CEA single chain Fvs: improved targeting by non-covalent dimers. Immunotechnology 2: 21-36, 1996.
19. Begent R H, Verhaar MJ, Chester KA, Casey JL, Green AJ, Napier MP, Hope-Stone LD, Cushen N, Keep PA, Johnson CJ, Hawkins RE, Hilson AJ and Robson L: Clinical evidence of efficient tumor targeting based upon single-chain Fv antibody selected from a combinatorial library. Nature Medicine 2: 979-984, 1996.
20. Yokota T, Milenic DE, Whitlow M and Schlom J: Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 52: 3402-3408, 1992.
21. Schier R, Marks JD, Wolf E, Apell G, Wong C, McCartney J, Bookman M, Huston J, Weiner LM and Adams GP: In vitro and in vivo characterization of a human anti-c-erB2 single chain Fv isolated from a filamentous pahge antibody library. Immunotechnology 1: 73-81, 1995.
22. Weiner LM, Houston LL, Huston JS, McCartney JE, Tai M-S, Apell G, Stafford WF, Bookman MA, Gallo JM and Adams GP: Improving the tumor-selective delivery of single-chain Fv molecules. Tumor Targeting 1: 51-60, 1995.
23. Adams GP, Schier R, McCall AM, Crawford S, Wolf EJ, Weiner M and Marks JD: Prolonged In vivo tumor retention of a human diabody targeting the extracellular domain of human HER2/neu. British J Cancer, In Press.
24. Dillman RO: Monoclonal antibodies for treating cancer. Annal Internal Med 111: 592-603, 1989.
25. Foon K A Biological response modifiers: the new immunotherapy. Cancer Res 49: 1621-1639, 1989.
26. 2 fragments in experimental ovarian cancer. Br J Cancer 65: 677-683, 1992.
27. 111In-labeled human tumor reactive monoclonal IgM AC6C3-2B 12. Cancer Res (Suppl) 55: 5736s-5742s, 1995.
28. Buchegger F, Halpern SE, Sutherland RM, Schreyer M and Mach J-P: In vitro and in vivo tumor models for studies of distribution of radiolabelled monoclonal antibodies and fragments. Nuklearmedizin 25: 207-209, 1986.
29. LeBerthon B, Khawli LA, Alauddin M, Miller GK, Charak BS, Mazumder A and Epstein AL: Enhanced tumor uptake of macromolecules induced by a novel vasoactive interleukin 2 immunoconjugate. Cancer Research 51: 2694-2698, 1991.
30. Hornick JL, Khawli LA, Hu P, Anderson PM, Gasson JC and Epstein AL: Antibody fusion proteins containing GM-CSF or IL-2 with specificity for B-cell malignancies exhibit enhanced effector functions while retaining tumor targeting properties. Proc Amer Assoc Cancer Res 38: 83, 1997.
31. Rosenblum M, Cheung L and Parakh C: Retargeting human cytokines: Directing TNF to HER2/NEU expressing tumor cells. Proc Amer Assoc Cancer Res 38: 488, 1997.
32. Delgado C, Francis GE and Fischer D Uses and properties of PEG-linked proteins. Crit Rev Ther Drug Carrier Syst 9: 249-304, 1992.
33. Pardridge WM, Kang YS, Yang J and Buciak JL: Enhanced cellular uptake and in vivo biodistribution of a monoclonal antibody following cationization. J Pharmaceutical Sciences 84: 943-948, 1995.
34. Tarburton JP, Halpern SE, Hagan PL, Sudora E, Chen A, Fridman DM and Pfaff AE: Effect of acetylation on monoclonal antibody ZCE-025 Fab': distribution in normal and tumor-bearing mice. Journal of Biological Response Modifiers 9: 221-230, 1990.
35. Purtell JN, Pesce AJ, Clyne DH, Miller NC and Pollak VF: Isoelectric point of albumin: effect on renal handling of albumin. Kidney Int 16: 366-376, 1979.
36. 2, and Fab in tumors. Cancer Res 49: 5656-5663, 1989.
37. Colcher D, Minelli F M, Roselli M, Muraro R, Simpson-Milenic D, and Schlom J: Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies, Cancer Res 48: 4597-4603, 1988.
38. Gallinger S, Reilly RM, Kirsh JC, Odze RD, Hay K, Polihronis J, Damani MT, Shpitz B and Stem HS: Comparitive dual label study of first and second generation antitumor-associated glycoprotein-72 monoclonal antibodies in colorectal cancer patients. Cancer Res 53: 271-278, 1993.
39. Juweid MN, R Paik, C Perez-Bacete, M Sato, J van Osdol W and Weinstein JN: Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for binding site barrier. Cancer Res 52: 5144-5153, 1992.
40. Roitt, I M, Brostoff J and Male DK: The antibody response Immunology, pp 84-85 St Louis: CV Mosby, 1985.
41. Marks JD, Griffiths AD, Malmqvist M, Clackson T, Bye JM and Winter G: By-passing immunisation: building high affinity human antibodies by chain shuffling. Bio/Technology 10: 779-783, 1992.
42. Schier R, McCall A, Adams GP, Marshall KW, Merritt H, Yim M, Crawford RS, Weiner LM, Marks C and Marks JD: Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J Mol Biol 263: 551-567, 1996.
43. Schier R, Bye J, Apell G, McCall A, Adams GP, Malmqvist M, Weiner LM and Marks JD: Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection, J Mol Biol 255: 28-43, 1996.
44. Adams G P, Schier R, McCall AM, Wolf EJ, Marks JD and Weiner LM: Tumor targeting properties of anti-c-erbB-2 single-chain Fv molecules over a wide range of affinities for the same epitope. Tumor Targeting 2: 154, 1996.
45. Wolf EA, Schreiber GJ, Cosand WL and Raff HV Monoclonal antibody homodimers: enhanced antitumor activity in nude mice. Cancer Res 53: 2560-2565, 1993.
46. Werlen R C, Lankinen M, Offord RE, Schubiger PA, Smith A and Rose K: Preparation of a trivalent antigen-binding construct using polyoxime chemistry: Imporved biodistribution and potential for therapeutic application. Cancer Res 56: 809-815, 1996.
47. 2, an anti-c-erbB-2 single-chain Fv dimer, mediated by stable radioiodine conjugation. J Nucl Med 36: 2276-2281, 1995.
48. Tai M-S, McCartney JE, Adams GP, Jin D, Hudziak RM, Oppermann H, Laminet AA, Bookman MA, Wolf EJ, Liu S, Stafford WF III, Fand I, Houston LL, Weiner LM and Huston JS: Targeting c-erbB-2 expressing tumors using single-chain Fv monomers and dimers. Cancer Res (Suppl) 55: 5983s-5989s, 1995.
49. Adams GP, McCartney JE, Wolf EJ, Tai M-S, Schier R, Stafford WF, Marks JD, Bookman MA, Huston JS and Weiner LM: Influence of avidity on the tumor retention of monospecific and bispecific anti-c-erbB-2 single-chain Fv dimers. Proc Amer Assoc Cancer Res 37: 472, 1996.
50. Carrasquillo JA: Radioimmunoscintography with polyclonal and monoclonal antibodies In: MR Zalutsky (ed) Antibodies in radiodiagnosis and therapy, pp 169-198 Boca Raton, FI: CRC Press, 1989.
51. Williams L E, Liu A, Wu AM, Odom-Maryon T, Chai A, Raubitschek AA and Wong JY: Figures of merit (FOMs) for imaging and therapy using monoclonal antibodies. Med Physics 22: 2025-2027, 1995.
52. Wilbur D S, Hadley SW, Hylarides MD, Abrams PG, Beaumier PA, Morgan AC, Reno JM and Fritzberg AR: Development of a stable radioiodinating reagent to label monoclonal antibodies for radiotherapy of cancer. J Nucl Med 30: 216-226, 1989.
53. Zalutsky M R, and Narula AS A method for the radiohalogenation of proteins resulting in decreased thyroid uptake of radioiodine, Int J Radiat Appl Instrum [Part A] 38: 1051-1055, 1987.
54. 125I]Iodophenethyl)maleimide antibody conjugate. Bioconj Chem 2: 435-440, 1991.
55. Deshpande SV, DeNardo SJ, Meares CF, McCall MJ, Adams GP and DeNardo GL: Effect of different linkages between chelates and monoclonal antibodies on the levels of radioactivity in the liver. Int J Radiat Appl Instrum [Part B] 16: 587-597, 1989.
56. Hnatowich DJ, Virzi F and Rusckowski M: Investigations of avidin and biotin for imaging applications. J Nucl Med 28: 1294-1302, 1987.
57. Paganelli G, Riva P, Deleide G, Clivio A, Chiolerio F, Scassellati GA, Malcovati M and Siccardi AG: In vivo labeling of biotinylated antibodies by radioactive avidin: a strategy to increase tumor radiolocalization. Int J Cancer 2 (suppl): 121-125, 1988.
58. Goodwin DA, Meares CF, McCall MJ, McTigue M and Chaovapong W: Pretargeted immunoscintography of murine tumors with indium-111 -labeled bifunctional haptens. J Nucl Med 29: 226-234, 1988.
59. 90Y delivery to mouse tumor xenografts, Tumor Targeting 2: 156-157, 1996.
60. Reno JM: Radioimmunotherapy of solid tumors with antibody pretargeting. Therapeutic Antibody Technology Meeting San Francisco, CA, 1995.
61. Deonarain MP, Spooner RA and Epenetos AA: Genetic delivery of enzymes for cancer therapy. Gene Therapy 2: 235-244, 1995.
62. Huston JS, George AJT, Adams GP, Stafford WF, Jamar F, Tai M-S, McCartney JE, Oppermann H, Heelan BT, Peters AM, Houston LL, Bookman MA, Wolf EJ and Weiner LM: Single-chain Fv radioimmunotargeting. Q J Nucl Med 40: 320-333, 1996.
63. Haunschild J, Faro H-P, Pack P and Pluckthun A Pharmacokinetic properties of bivalent miniantibodies and comparison to other immunoglobulin forms. Antibody, Immunoconj Radiopharm 8: 111-128, 1995.
64. Zimmer A M, Rosen ST, Spies SM, Polovina MR, Minna JD Spies WC and Silverstein EA Radioimmunoimaging of human small cell lung carcinoma with I-131 tumor specific monoclonal antibody. Hybridoma 4: 1-11, 1985.
65. Demignot S. Pimm MV. Baldwin RW: Comparison of distribution of 791 T/36 monoclonal antibody and its Fab/c fragment in BALB/c and nude mice bearing human tumor xenografts. Cancer Res 50: 2936-2942, 1990.